Idh1 Mutant Glioma clinical trials

Explore recruiting idh1 mutant glioma clinical trials.

Recruiting idh1 mutant glioma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idh1 Mutant Glioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma

Netherlands, Germany, France, Austria, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Idh1 Mutant Glioma trials by city

Idh1 Mutant Glioma in Toronto Idh1 Mutant Glioma in Vancouver Idh1 Mutant Glioma in Montreal Idh1 Mutant Glioma in Calgary Idh1 Mutant Glioma in Edmonton Idh1 Mutant Glioma in Ottawa Idh1 Mutant Glioma in Winnipeg Idh1 Mutant Glioma in Quebec City Idh1 Mutant Glioma in Hamilton Idh1 Mutant Glioma in Kitchener Idh1 Mutant Glioma in London Idh1 Mutant Glioma in Halifax Idh1 Mutant Glioma in New York Idh1 Mutant Glioma in Los Angeles Idh1 Mutant Glioma in Chicago Idh1 Mutant Glioma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease